ArticlePediatric nephrology (Berlin, Germany)2026
Incidence of and risk factors for chronic kidney disease in childhood cancer survivors.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough therapeutic advances have improved the life expectancy of children with cancer, the late complication of chronic kidney disease (CKD) represents a challenge. We aimed to measure the cumulative incidence and identify risk factors for CKD, defined as estimated glomerular filtration rate < 90 mL/min/1.73 m
methodsWe studied children treated for cancer who survived for ≥ 5 years. The cumulative incidence of CKD was measured and risk factors were identified using the Kaplan-Meier method, the log-rank test, and Cox proportional hazards analysis.
resultsEighty-four survivors, with a median of 5.7 years old at treatment initiation, were studied for a median of 9.0 years. Nineteen, 12, 15, 57, 7 (of 78), 4, 20, 14, and 34 patients received cisplatin, carboplatin, ifosfamide, methotrexate, aminoglycoside, nephrectomy, total-body irradiation, kidney irradiation (≥ 10 Gy), and hematopoietic stem cell transplantation, respectively; and 14 developed relapse/secondary cancer. During treatment, acute kidney injury developed in 57.5% of patients. The cumulative incidence of CKD was 10.7% after 5 years and 21.8% after 10 years. The log-rank test identified older age (≥ 5 years) at treatment initiation, solid tumor, cisplatin therapy, ifosfamide therapy, and nephrectomy as significant risk factors; and a Cox proportional hazards model showed that older age (HR 3.89, p = 0.033), cisplatin therapy (HR 8.80, p < 0.001), and nephrectomy (HR 10.20, p = 0.016) were significant risk factors.
conclusionsThe long-term monitoring of kidney function is especially important for survivors of childhood cancer who received their initial treatment at an older age, underwent cisplatin-based chemotherapy, or underwent nephrectomy.
Indexed as
Identifiers
41073615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.